UK court reaffirms its stringent plausibility standard in AstraZeneca despite G 2/21 By Annsley Merelle Ward on Friday, May 09, 2025 #IPKat AstraZeneca epc G 2/21 Michael Tappin QC patent litigation plausibility SPC sufficiency Teva UK +
Sweden gets into the Article 3 SPC referral game in AstraZeneca dapagliflozin case By Henry P Yang on Wednesday, March 01, 2023 article 3(a) article 3(c) patents royalty pharma SPC supplementary protection certificates Sweden Teva +
Keeping up with Belgian patent litigation: Year case law review 2020 By Annsley Merelle Ward on Tuesday, July 13, 2021 amerikat; belgium belgian patent litigation CJEU Enforcement Directive keeping up with mylan SPC regulation Teva +
BREAKING: Court of Appeal frames Article 3(a) test as one of "claim requirement", but still upholds Truvada SPC invalidity By Annsley Merelle Ward on Thursday, December 19, 2019 #IPKat Actavis v Boehringer AG Opinion article 3(a) CJEU Court of Appeal Lilly v HGS Lord Justice Arnold lord justice floyd medeva regulatory approval SPC regulation Teva Teva v Gilead +
UCL IBIL Event: Boris v Corbyn v Trump - putting a price on patents, medicine and innovation By Annsley Merelle Ward on Friday, November 22, 2019 #IPKat AmeriKat compulsory licensing crown use ibil IP and pharma mr justice birss NHS Novartis open access open innovation Teva trade agreement ucl UK politics +
The novelty of “on sale inventions” under a confidentiality agreement with regards to an “on sale” invention: the US Supreme Court rules By Frantzeska Papadopoulou on Thursday, January 31, 2019 "on sale" America Invents Act Frantzeska Papadopoulou Helsinn novelty requirement patent infringement Teva +